DE69433994D1 - Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron - Google Patents

Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron

Info

Publication number
DE69433994D1
DE69433994D1 DE69433994T DE69433994T DE69433994D1 DE 69433994 D1 DE69433994 D1 DE 69433994D1 DE 69433994 T DE69433994 T DE 69433994T DE 69433994 T DE69433994 T DE 69433994T DE 69433994 D1 DE69433994 D1 DE 69433994D1
Authority
DE
Germany
Prior art keywords
precursors
dehydroepiandrosterone
treatment
prevention
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433994T
Other languages
English (en)
Other versions
DE69433994T2 (de
Inventor
Fernand Labrie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDORECH Inc
Endorecherche Inc
Original Assignee
ENDORECH Inc
Endorecherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/180,361 external-priority patent/US5776923A/en
Application filed by ENDORECH Inc, Endorecherche Inc filed Critical ENDORECH Inc
Application granted granted Critical
Publication of DE69433994D1 publication Critical patent/DE69433994D1/de
Publication of DE69433994T2 publication Critical patent/DE69433994T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
DE69433994T 1993-01-19 1994-01-19 Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron Expired - Lifetime DE69433994T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5619 1979-01-22
US561993A 1993-01-19 1993-01-19
US08/180,361 US5776923A (en) 1993-01-19 1994-01-18 Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US180361 1994-01-18
PCT/CA1994/000022 WO1994016709A2 (en) 1993-01-19 1994-01-19 Therapeutic uses and delivery systems of dehydroepiandrosterone

Publications (2)

Publication Number Publication Date
DE69433994D1 true DE69433994D1 (de) 2004-10-21
DE69433994T2 DE69433994T2 (de) 2005-09-22

Family

ID=26674550

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69433994T Expired - Lifetime DE69433994T2 (de) 1993-01-19 1994-01-19 Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
DE69434697T Expired - Lifetime DE69434697T2 (de) 1993-01-19 1994-01-19 Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69434697T Expired - Lifetime DE69434697T2 (de) 1993-01-19 1994-01-19 Therapeutische Verwendungen von Dehydroepiandrosteron zur Behandlung von verminderter Libido und Osteoporose

Country Status (18)

Country Link
US (7) US5872114A (de)
EP (1) EP0680327B1 (de)
JP (1) JP3441730B2 (de)
CN (2) CN1439375B (de)
AT (2) ATE275957T1 (de)
AU (2) AU686120B2 (de)
CZ (1) CZ297860B6 (de)
DE (2) DE69433994T2 (de)
DK (1) DK0680327T3 (de)
ES (2) ES2261836T3 (de)
FI (1) FI953017A (de)
HU (1) HU228385B1 (de)
IL (1) IL108371A (de)
NO (6) NO952417D0 (de)
NZ (2) NZ250712A (de)
PT (2) PT1382340E (de)
SK (1) SK286051B6 (de)
WO (1) WO1994016709A2 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407927A (en) * 1993-04-16 1995-04-18 The Regents Of The University Of California Treatment of mild depression and restoration of IGF-I levels in aging by dehydroepiandrosterone
FR2729854A1 (fr) * 1995-01-26 1996-08-02 Oreal Utilisation du sulfate de dehydroepi-androsterone dans une composition cosmetique ou dermatologique
US20020032160A1 (en) * 1995-02-24 2002-03-14 Nyce Jonathan W. Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
US5660835A (en) * 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
ES2098193B1 (es) * 1995-07-21 1997-12-01 Gomez Jesus Calderon Nueva formulacion farmaceutica de dehidroepiandrosterona para aplicacion topica percutanea.
DE19619045C1 (de) * 1996-05-02 1997-11-13 Jenapharm Gmbh Verwendung von Kombinationspräparaten zur Behandlung hypogonadaler Männer sowie Männern mit Hypophysenerkrankungen
US6228852B1 (en) 1996-07-12 2001-05-08 Carolyn V. Shaak Transdermal application of naturally occurring steroid hormones
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6015786A (en) 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US7169768B1 (en) * 1997-03-18 2007-01-30 Weisman Kenneth M Method of decreasing atherosclerosis and its complications
US5912240A (en) 1997-04-10 1999-06-15 Loria; Roger M. 5-androstene 3β, 17α diol as an inhibitor of tumor growth
IT1291141B1 (it) * 1997-04-16 1998-12-29 Sigma Tau Ind Farmaceuti Composizione farmaceutica comprendente una alcanoil l-carnitina, atta a stimolare la moltiplicazione e la crescita degli osteoblasti
US6140315A (en) * 1997-06-09 2000-10-31 Weisman; Kenneth M. Therapeutic uses of goserelin acetate
WO1999007381A1 (en) * 1997-08-11 1999-02-18 Weider Nutrition International, Inc. Compositions and treatments to reduce side effects of administration of androgenic testosterone precursors
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
US6093389A (en) * 1997-12-01 2000-07-25 American Cyanamid Company Methods and compositions for attracting and controlling termites
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
CN1879630A (zh) * 1998-06-11 2006-12-20 内部研究股份有限公司 雄－5－烯－3β,17β－二醇的药物组合物及其用途
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
FR2789312B1 (fr) * 1999-02-05 2003-10-17 Seporga Sterol 3 sulfates, nouveaux principes actifs a usage cosmetique et dermatologique, et leurs applications
US7045513B1 (en) * 1999-03-18 2006-05-16 Genelabs Technologies, Inc. DHEA composition and method
JP5005127B2 (ja) 1999-05-04 2012-08-22 ストラカン・インターナショナル・リミテッド アンドロゲングリコシド及びそのアンドロゲン作用活性
AU2004222794B2 (en) * 1999-06-11 2007-03-08 Watson Pharmaceuticals, Inc. Non-oral androgenic steroids for women
CA2376797C (en) * 1999-06-11 2011-03-22 Watson Pharmaceuticals, Inc. Administration of non oral androgenic steroids to women
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
AU7896100A (en) * 1999-10-14 2001-04-23 Endorecherche Inc. Selective estrogen receptor modulators in the treatment or reduction of the riskof acquiring hypertension, cardiovascular diseases, and insulin resistance
FR2803750B1 (fr) * 2000-01-17 2004-04-02 Assist Publ Hopitaux De Paris Utilisation par voie orale de la dehydroepiandrosterone, de ses precurseurs biologiques et de ses derives metaboliques comme anti-atrophiant
US7241753B2 (en) 2000-02-25 2007-07-10 Loria Roger M Method of treatment of prostate cancer
FR2807323A1 (fr) 2000-04-10 2001-10-12 Oreal Composition, notamment cosmetique, renfermant un steroide et un 2-alkyl alcanol ou un ester
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
BR0113649A (pt) * 2000-08-30 2004-07-20 Unimed Pharmaceuticals Inc Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
FR2826011B1 (fr) * 2001-06-14 2004-12-10 Oreal Nouveaux derives de la 7-oxo-dhea et utilisation cosmetique
MXPA03011910A (es) * 2001-06-18 2004-06-03 Noven Pharma Suministro de medicamento mejorado en sistemas transdermicos.
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US6805878B2 (en) 2001-09-13 2004-10-19 Noven Pharmaceuticals, Inc. Transdermal administration of ACE inhibitors
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
DE60218881T2 (de) * 2001-11-15 2007-12-20 Pantarhei Bioscience B.V. Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
AU2003206442A1 (en) * 2002-02-21 2003-09-09 Pantarhei Bioscience B.V. Estrogenic component for treating decreased libido in women
CA2481310A1 (en) * 2002-04-03 2003-10-16 Barr Laboratories, Inc. Step-down estrogen therapy
AU2003224561A1 (en) * 2002-04-23 2003-11-10 Sahltech I Goteborg Ab Use of dhea for treatment of female hypopituitarism
AU2003269889B2 (en) * 2002-06-17 2007-04-19 Epigenesis Pharmaceuticals, Llc Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
US7405207B2 (en) * 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
WO2004091535A2 (en) * 2003-04-11 2004-10-28 Barr Laboratories, Inc. Methods of administering estrogens and progestins
US20090285900A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026848A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20110209699A1 (en) * 2003-07-31 2011-09-01 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090285899A1 (en) * 2003-07-31 2009-11-19 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a methylxanthine derivative for treatment of asthma or chronic obstructive pulmonary disease
US20050026880A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
US20050026884A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
US20090297611A1 (en) * 2003-07-31 2009-12-03 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050101545A1 (en) * 2003-07-31 2005-05-12 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050113318A1 (en) * 2003-07-31 2005-05-26 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US20050043282A1 (en) * 2003-07-31 2005-02-24 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US8147472B2 (en) 2003-11-24 2012-04-03 Kimberly-Clark Worldwide, Inc. Folded absorbent product
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
CA2584524C (en) 2004-10-20 2012-02-07 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
AP2007003982A0 (en) * 2004-11-01 2007-06-30 Endorech Inc Use of androgens to reduce the likelihood of acquring or to treat skin aging
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
PL1868614T3 (pl) 2005-03-24 2013-01-31 Univ Emory Schemat dawkowania do leczenia urazowego uszkodzenia mózgu progesteronem
US8084446B2 (en) * 2005-04-26 2011-12-27 Eric Marchewitz Use of DHEA derivatives for enhancing physical performance
PT1937276E (pt) 2005-10-12 2013-02-21 Besins Healthcare Luxembourg Gel de testosterona melhorado e método para a sua utilização
US20090215731A1 (en) * 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US9381193B2 (en) * 2011-04-01 2016-07-05 Washington University Contraceptive methods and compositions
US9066956B2 (en) 2011-12-29 2015-06-30 Universidad De Chile Vaginal ring comprising DHEA or DHEA sulfate and optionally a release-modulating agent of the active principle, useful to increase the ovarian reserve in women and to relieve symptoms associated with menopause
EP3057667B1 (de) * 2013-10-15 2020-03-04 CHelac Holding GmbH Steroid-carbonsäureester, zusammensetzungen, enthaltend steroid-carbonsäureester und verwendung dieser bei lokal topischer applikation für kosmetische oder dermatologische zwecke
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US10064874B2 (en) 2014-10-22 2018-09-04 Havah Therapeutics Pty Ltd. Methods of reducing mammographic breast density and/or breast cancer risk
CA3002562A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
JP7287606B2 (ja) 2018-08-10 2023-06-06 株式会社日本スペリア社 鉛フリーはんだ合金
CN114599369A (zh) 2019-06-03 2022-06-07 哈瓦赫治疗有限公司 用于递送雄激素剂和芳香酶抑制剂的药物制剂和系统以及使用方法
US11690852B2 (en) 2020-12-01 2023-07-04 Endorecherche. Inc. Reduction of the incidence or recurrence of breast cancer in postmenopausal women treated with intravaginal sex steroid precursor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK122125B (da) * 1967-10-04 1972-01-24 Schering Ag Analogifremgangsmåde til fremstilling af terapeutisk aktive carboxylsyreestere af 3β-hydroxy-5-androstan-17-on(dehydroepiandrosteron) med 7-11 carbonatomer i esterresten.
US3551554A (en) * 1968-08-16 1970-12-29 Crown Zellerbach Corp Enhancing tissue penetration of physiologically active agents with dmso
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3742951A (en) * 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
JPS505372A (de) * 1973-05-30 1975-01-21
US4006218A (en) * 1974-07-08 1977-02-01 Johnson & Johnson Potentiated medicaments
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4005200A (en) * 1975-07-17 1977-01-25 Kanebo, Ltd. Method for improving the maturity of the parturient canal and the sensitivity to oxytocin
DE2534911C2 (de) * 1975-08-01 1985-04-18 Schering AG, 1000 Berlin und 4709 Bergkamen Verfahren zur Herstellung von 5-Androsten-17-on-Derivaten
US4213978A (en) * 1978-12-05 1980-07-22 Interx Research Corporation Anti-acne and anti-seborrhea prodrug derivatives of progesterone
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
FR2518879A1 (fr) * 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4397782A (en) * 1982-05-28 1983-08-09 E. R. Squibb & Sons, Inc. Antiinflammatory 17-spiroandrostenes
US4496556A (en) * 1982-08-16 1985-01-29 Norman Orentreich Topical applications for preventing dry skin
US4542129A (en) * 1982-08-16 1985-09-17 Norman Orentreich DHEA Formulations and methods for treating dry skin
SE8303031D0 (sv) * 1983-05-30 1983-05-30 Leo Ab Improved steroid esters preparation
US4518595A (en) * 1983-07-19 1985-05-21 The Jackson Laboratory Method for treating diabetes using DHEA compounds
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
WO1986004236A1 (en) * 1985-01-25 1986-07-31 Monell Chemical Senses Center The use of male essence, including androstenol and dehydroepiandrosterone sulfate to treat luteal phase defects and failure to ovulate in human females
US4628052A (en) * 1985-05-28 1986-12-09 Peat Raymond F Pharmaceutical compositions containing dehydroepiandrosterone and other anesthetic steroids in the treatment of arthritis and other joint disabilities
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
US4812447A (en) * 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
JPS63104924A (ja) * 1986-10-20 1988-05-10 Kanebo Ltd 膣坐剤
US4816258A (en) * 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
NL194728C (nl) * 1987-04-16 2003-01-07 Hollis Eden Pharmaceuticals Farmaceutisch preparaat geschikt voor de profylaxe of therapie van een retrovirale infectie of een complicatie of gevolg daarvan.
JPS63267722A (ja) * 1987-04-27 1988-11-04 Daiichi Yakuhin Sangyo Kk 抗肥満症剤
US4835147A (en) * 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
DE3856508T2 (de) * 1987-09-24 2002-06-06 Jencap Res Ltd Oestrogen und Progestin enthaltende Verhütungspackungen
US5064654A (en) * 1989-01-11 1991-11-12 Ciba-Geigy Corporation Mixed solvent mutually enhanced transdermal therapeutic system
US5162037A (en) * 1988-04-01 1992-11-10 Whitson Laboratories, Inc. Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
KR900701242A (ko) * 1988-12-01 1990-12-01 스타이너 브이. 캔스타드 에스트라디올의 경피전달용 조성물
ZA901847B (en) * 1989-03-10 1991-10-30 Endorecherche Inc Combination therapy for the treatment of estrogen sensitive diseases
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
GB9003939D0 (en) * 1990-02-21 1990-04-18 Imperial College Sulphatase inhibitors
US5071644A (en) * 1990-08-07 1991-12-10 Mediventures, Inc. Topical drug delivery with thermo-irreversible gels
US5110810A (en) * 1991-02-08 1992-05-05 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of platelet aggregation
US5162198A (en) * 1991-02-08 1992-11-10 Virginia Commonwealth University Method of using dehydroepiandrosterone and dehydroepiandrosterone-sulfate as inhibitors of thrombuxane production and platelet aggregation
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
ZA924811B (en) * 1991-06-28 1993-12-29 Endorecherche Inc Controlled release systems and low dose androgens

Also Published As

Publication number Publication date
US5854229A (en) 1998-12-29
NO20003549L (no) 1995-06-16
AU5855794A (en) 1994-08-15
FI953017A0 (fi) 1995-06-19
CN1439375A (zh) 2003-09-03
NO20024189D0 (no) 2002-09-03
NO20003545D0 (no) 2000-07-10
NZ250712A (en) 1996-11-26
NO321846B1 (no) 2006-07-10
CN1116823A (zh) 1996-02-14
NZ512334A (en) 2005-05-27
NO315690B1 (no) 2003-10-13
DE69434697T2 (de) 2007-03-29
NO952417L (no) 1995-06-16
PT1382340E (pt) 2006-07-31
NO20024189L (no) 1995-06-16
SK286051B6 (sk) 2008-02-05
NO20003546L (no) 1995-06-16
JP3441730B2 (ja) 2003-09-02
WO1994016709A2 (en) 1994-08-04
CZ297860B6 (cs) 2007-04-18
ES2227523T3 (es) 2005-04-01
US5948434A (en) 1999-09-07
PT680327E (pt) 2004-12-31
ATE322271T1 (de) 2006-04-15
IL108371A (en) 2009-09-01
HUT73241A (en) 1996-07-29
WO1994016709A3 (en) 1994-11-24
HU9501985D0 (en) 1995-09-28
NO20003549D0 (no) 2000-07-10
NO20003547L (no) 1995-06-16
US5798347A (en) 1998-08-25
IL108371A0 (en) 1994-04-12
DE69433994T2 (de) 2005-09-22
JPH08505629A (ja) 1996-06-18
NO952417D0 (no) 1995-06-16
NO20003546D0 (no) 2000-07-10
AU5388494A (en) 1994-07-28
CN1100541C (zh) 2003-02-05
NO314656B1 (no) 2003-04-28
ES2261836T3 (es) 2006-11-16
NO314067B1 (no) 2003-01-27
EP0680327A1 (de) 1995-11-08
NO20003547D0 (no) 2000-07-10
AU686120B2 (en) 1998-02-05
FI953017A (fi) 1995-06-19
SK77995A3 (en) 1997-04-09
DK0680327T3 (da) 2005-01-03
US5837700A (en) 1998-11-17
CN1439375B (zh) 2012-08-08
HU228385B1 (en) 2013-03-28
DE69434697D1 (de) 2006-05-18
NO20003545L (no) 1995-06-16
CZ156595A3 (en) 1995-12-13
US5872114A (en) 1999-02-16
US5843932A (en) 1998-12-01
ATE275957T1 (de) 2004-10-15
EP0680327B1 (de) 2004-09-15
US5807849A (en) 1998-09-15

Similar Documents

Publication Publication Date Title
ATE275957T1 (de) Therapeutische verwendungen und verabreichungsysteme von dehydroepiandrosteron
MY157883A (en) Therapeutic uses and delivery systems of dehydroepiandrosterone
AR018660A1 (es) Una composicion farmaceutica que comprende androst-5-en-3beta,17beta-diol o una prodroga del mismo; un kit y metodos terapeuticos que utilizan dicha composicion y un parche transdermico.
KR970706001A (ko) 습식-과립화를 통해 투여단위를 제조하는 방법 (process of making dosage units by wet granulation)
ATE452641T1 (de) Orale pharmazeutische zusammensetzung enthaltend 15-hydroxytestosteron und seine derivate
Gompel et al. Tibolone actions on normal and breast cancer cells
GB2138286A (en) Pharmaceutical composition for the treatment of hair loss
IE34308B1 (en) 11beta,13beta dialkylgona-1,3,5(10)-trien-3-ol 3-cycloalkyl ethers
CA2491801A1 (fr) Composes a base d'hormone donneurs de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
BR0116127A (pt) Composto, composição farmacêutica, uso de um composto, e, conjunto para a contracepção masculina
GB1244143A (en) Trialkyl-silyloxy-steroids
TAGA et al. Distribution and cyclic change of aromatase cytochrome P-450 activity in human uteri
ITBA920007A1 (it) Formulazioni farmaceutiche per la somminstrazione sistemica per via nasale degli ormoni sessuali femminili naturali e di ormoni ad
Nimrod et al. 88. Aromatization of androgens by human fat tissue
Ellis 90. Control of rat testicular 5α-reductase activity for testosterone and progesterone: blinding, X-irradiation, melatonin, prolactin, LH, and FSH
Loke 89. Androsta-1, 4-diene-3, 17, 19-trione: Its provisional identification as a new placental metabolite of androstenedione
GB1138460A (en) Steroid compounds
Tinneberg et al. Steroide fördern Brustkrebs
GB1071207A (en) Improvements in or relating to 6,6-ethylene corticoids

Legal Events

Date Code Title Description
8364 No opposition during term of opposition